References
- Møller CT, Fosså SD, Tafjord G, et al. Primary versus secondary muscle-invasive bladder cancer: survival after curative treatment. Scand J Urol. 2022;56(3):1–7.
- Yiou R, Patard JJ, Benhard H, et al. Outcome of radical cystectomy for bladder cancer according to the disease type at presentation. BJU Int. 2002;89(4):374–378.
- Lee CT, Dunn RL, Ingold C, et al. Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion. Urology. 2007;69(6):1068–1072.
- de Vries RR, Nieuwenhuijzen JA, Vincent A, et al. Survival after cystectomy for invasive bladder cancer. Eur J Surg Oncol. 2010;36(3):292–297.
- Kotb AF, Kovac E, Kassouf W, et al. Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes? World J Urol. 2012;30(6):761–767.
- Aziz A, Gierth M, Fritsche HM, et al. Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy. Urol Int. 2013;91(1):97–102.
- Breau RH, Karnes RJ, Farmer SA, et al. Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis. BJU Int. 2014;113(6):900–906.
- May M, Burger M, Brookman-May S, et al. EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer. Clin Genitourin Cancer. 2014;12(4):278–286.
- Moschini M, Sharma V, Dell'oglio P, et al. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU Int. 2016;117(4):604–610.
- Pietzak EJ, Zabor EC, Bagrodia A, et al. Genomic differences between "primary" and "secondary" muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy. Eur Urol. 2019;75(2):231–239.
- Lusty A, Doiron RC, Booth CM, et al. No outcome differences after cystectomy between patients with De novo muscle-invasive bladder cancer compared to progressors: a retrospective population-based study. J Urol. 2021;206(2):260–269.
- Grossmann NC, Rajwa P, Quhal F, et al. Comparative outcomes of primary versus recurrent high-risk non-muscle-invasive and primary versus secondary muscle-invasive bladder cancer after radical cystectomy: results from a retrospective multicenter study. Eur Urol Open Sci. 2022;9:14–21.
- Benidir T, Lone Z, Zhang A, et al. Comparing pathologic and survival outcomes between primary and secondary muscle invasive bladder cancer when treated by radical cystectomy with or without neoadjuvant chemotherapy. Urology. 2022;S0090-4295(22):00514–00513.
- May M, Bastian PJ, Brookman-May S, et al. Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. Scand J Urol Nephrol. 2011;45(4):251–257.
- Bobjer J, Hagberg O, Aljabery F, et al. A population-based study on the effect of a routine second-look resection on survival in primary stage T1 bladder cancer. Scand J Urol. 2021;55(2):108–115.
- Babjuk M, Burger M, Capoun O, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75–94.